Related Experiment Video
Updated: Jan 4, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
Haiyun Wang1, Qi Lv1, Yue Xu1
1School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Background:
KRAS mutations are the most frequent oncogenic aberration in lung adenocarcinoma. KRAS mutant isoforms differentially shape tumour biology and influence drug responses. This heterogeneity challenges the development of effective therapies for patients with KRAS-driven non-small cell lung cancer (NSCLC).
Methods:
We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12). We validated our predictive in silico results with in vitro models using gene knockdown, pharmacological target inhibition and reporter assays.
Findings:
Our computational analysis identifies casein kinase 2A1 (CSNK2A1) as a mediator of MEK/ERK inhibitor resistance in KRAS(G12C) mutant lung cancer cells. CSNK2A1 knockdown reduces cell proliferation, inhibits Wnt/β-catenin signalling and increases the anti-proliferative effect of MEK inhibition selectively in KRAS(G12C) mutant lung cancer cells. The specific CK2-inhibitor silmitasertib phenocopies the CSNK2A1 knockdown effect and sensitizes KRAS(G12C) mutant cells to MEK inhibition.
Interpretation:
Our study supports the importance of accurate patient stratification and rational drug combinations to gain benefit from MEK inhibition in patients with KRAS mutant NSCLC. We develop a genotype-based strategy that identifies CK2 as a promising co-target in KRAS(G12C) mutant NSCLC by using available pharmacogenomics gene expression datasets. This approach is applicable to other oncogene driven cancers. FUND: This work was supported by grants from the National Natural Science Foundation of China, the National Key Research and Development Program of China, the Lung Cancer Research Foundation and a Mildred-Scheel postdoctoral fellowship from the German Cancer Aid Foundation.
Insights
Targeting casein kinase 2A1 (CK2) alongside MEK inhibitors shows promise for treating KRAS G12C-mutant lung cancer. This combination therapy overcomes resistance and enhances anti-cancer effects in non-small cell lung cancer (NSCLC).
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- KRAS mutations are common in lung adenocarcinoma, leading to diverse tumor biology and drug responses.
- Therapeutic strategies for KRAS-driven non-small cell lung cancer (NSCLC) are challenged by this heterogeneity.
- Developing effective treatments for KRAS mutant NSCLC requires understanding resistance mechanisms.
Purpose of the Study:
- To identify novel drug targets for overcoming MEK/ERK inhibitor resistance in KRAS G12C-mutant lung cancer.
- To develop a genotype-based strategy for rational drug combinations in NSCLC treatment.
- To validate computational predictions with in vitro experimental models.
Main Methods:
- Integrative pharmacogenomics analysis of 12 KRAS G12C-mutant lung cancer cell lines.
- In silico identification of potential drug targets mediating MEK/ERK inhibitor resistance.
- In vitro validation using gene knockdown, pharmacological inhibition, and reporter assays.
Main Results:
- Casein kinase 2A1 (CSNK2A1) was identified as a key mediator of MEK/ERK inhibitor resistance.
- CSNK2A1 knockdown reduced proliferation, inhibited Wnt/β-catenin signaling, and enhanced MEK inhibition effects.
- The CK2 inhibitor silmitasertib mimicked CSNK2A1 knockdown and sensitized KRAS G12C cells to MEK inhibitors.
Conclusions:
- CK2 is a promising co-target for KRAS G12C-mutant NSCLC, enhancing MEK inhibitor efficacy.
- Accurate patient stratification and rational drug combinations are crucial for MEK inhibitor benefit in NSCLC.
- This genotype-based strategy is applicable to other oncogene-driven cancers.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38The Ras Gene
Ras is a...